Posts tagged closely-held
Appili readies antibiotic bridging study

Closely-held Appili Therapeutics plans to begin late in the current quarter a Phase 1 bridging, or bioequivalence, study of its lead anti-infective, ATI-1501, a reformulated, taste-masked liquid suspension of metronidazole, targeting anaerobic bacterial infections, including Clostridium difficile.

Read More
Vyome completing enrollment in acne POC trial

Closely-held Vyome Biosciences expects to enroll the final patient next month in a proof-of-concept clinical trial in the U.S. of its lead molecule for drug-resistant acne, VB 1953.

Read More
In conversation with Paul Gunn

As president and CEO of closely-held Soricimed Biopharma, Paul Gunn parlayed a 20-year career as a financial executive into funding the startup of Soricimed along with a tech transfer in 2005 facilitated by Mount Allison University in Sackville, New Brunswick, Canada. Admittedly, he was new to biotech and drug development in those days, but he moved into Soricimed as CFO in 2007 and became CEO a few years later. Today, the company is gaining an international following with its anti-cancer drug candidate, SOR-C13, and successful early human studies in solid cancer types. The company presented four posters at the American Association of Cancer Research in New Orleans last week about its preclinical and clinical research and supporting data. In this interview with, Mr. Gunn discusses the early success of SOR-C13 and the drug’s future potential.

Read More
Xagenic readies X1 molecular diagnostic beta trials

Closely-held Xagenic plans to conduct beta studies this year, in advance of a major chlamydia and gonorrhea clinical trial, with its rapid X1 molecular diagnostic testing system in preparation for market launches in Europe and the U.S.

“The Xagenic X1 platform is a revolutionary diagnostic sys­tem that allows the user to perform lab-quality molecular assays in a physician’s office or other clinical care setting, with a time-to-result of 20 minutes or less,” Ihor Boszko, VP of business development, says in an interview with “This system is poised to transform the way healthcare is delivered.”

Mr. Boszko explains that the X1 instrument has been carefully designed to meet the requirements for use in a physician’s office, including its compact size, affordable pricing and ease of use.

Read More